# Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

> **NCT07415980** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 68 (estimated)

## Conditions studied

- Double Expressor DLBCL

## Interventions

- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Rituximab (R)
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT07415980
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07415980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07415980, "Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07415980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*